01 July 2004
DNA released from ischemic and rejecting organs as an indicator of graft cellular damage.
B Interewicz, W L Olszewski, M Sikora, K Gorna, B KolakowskaAnn Transplant 2004; 9(2): 42-45 :: ID: 142783
Abstract
Donor cellular debris contains fragments of nuclei with genetic material.The question arises whether the amount of donor graft released DNA accumulating in the recipient lymphoidtissues after transplantation could be a measure of donor organ damage caused by ischemia and preservationas well as rejection. We found that donor heart passenger cells do not contribute to the DNA disseminatedin the recipient. All donor DNA was, then, derived from the damaged graft cells. Immediately and 1 dayafter transplantation, it was present in blood (plasma and cells) to accumulate later in the spleen.Higher values of donor DNA in the syngeneic than allogeneic combination, most evident on day 7, werepresumably due to better perfusion of graft not undergoing rejection. Immunosuppression attenuated donorDNA release and accumulation in recipient tissues, nevertheless, relatively high concentrations couldstill be detected. Further studies are in progress on the usefulness of measuring DNA concentration forevaluation of the graft damage.
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






